Small Pharmaceuticals
Market Cap
₹5,442 ₹5,442 Cr.
P/E
18.60
PEG
1.81
PEG = P/E ÷ 5yr forward EPS CAGR
5yr forward EPS CAGR thesis · Base case

The base case depends on a gradual Domestic Formulations recovery plus a sustained Export Formulations recovery, with both together driving most incremental revenue.

The bear case is triggered by export recovery delays concurrent with domestic run-rate weakness; the bull case requires faster export conversion and stronger domestic sales.

Watch regulatory approvals, US supply recovery, and domestic secondary-sales disclosures as the key validation points.

Key Ratios

Debt to Equity
Debt to Equity
-
Div Yield (%)
Div Yield (%)
1.50
Individual < 2 lac
Individual < 2 lac
13.41 %
Institutions
Institutions
7.71 %
Market cap
Market cap
5,442 Cr
No. of Shareholders
No. of Shareholders
55,045
OPM (%)
OPM (%)
15.32 %
PE
PE
18.60
Prom Holding
Prom Holding
69.66 %
ROCE (%)
ROCE (%)
11.60
ROE (%)
ROE (%)
11.32
Sales
Sales
2,190 Cr
  • FDC
  • Orchid Pharma
  • Guj. Themis Biosyn
  • TJI Pharma - Small Cap
Last updated on 25 Sep 2026
  • FDC makes branded formulations sold mainly in India, led by oral rehydration drink Electral, anti-infective Zifi, energy drink Enerzal and anti-fungal Zocon.
  • Export formulations and bulk drugs are smaller parts of sales. It sells mainly in India and in the United States, United Kingdom and South Africa.
  • Domestic formulations are the core at 82% of revenue. United States eye-care supplies are small and growing. Partner profit shares make that part volatile.
  • Its oral rehydration drink Electral holds about 70% of that category. No single customer is above 10% of revenue.
  • Per management, it is expanding in United States eye-care and domestic innovation. It remains debt-free. It pays regular dividends.
  • Profit in coming quarters depends on domestic recovery holding. It also needs steadier United States profit shares.
  • Its core domestic brands face fatigue and strong competition.
  • New corporate and research building was Mar 2026; no update since
    completion will show final cost and timing.
  • Domestic recovery check ~Nov 2026
    the print shows if domestic growth holds. It also shows if United States supplies stay steady.
Price Range

See where the stock is trading versus its 52-week high and low.

Low
313
52W Range
High
474
Timeline

Key company specific updates.

Custom financial statement

Edit rows

Forensics

8 Yes

Positive for this company

2 Neutral

Neutral for this company

7 No

Negative for this company

0 No Data

Insufficient data to analyse

Market Share

0.15 %
(as of Jul 22)
Anti - Diabetes - Market Share
2.78 %
(as of Jul 22)
Anti-Infectives - Market Share
0.03 %
(as of Feb 21)
Anti-Malarial - Market Share
0.75 %
(as of Nov 21)
Blood Related - Market Share
0.29 %
(as of Jul 22)
Cardiovascular - Market Share
0.54 %
(as of Nov 21)
Dermatology - Market Share

Revenue mix

Product Wise Break-Up

Therapeutic Area Wise Break-Up - Domestic

Location Wise Break-Up - Formulation

Location Wise Break-Up - Bulk Drugs

Location Wise Break-Up

Operational Metrics

    Select a Metric
    • Domestic Sales Growth - YoY (%)
    • R&D as a % of Total Sales (%)

    Peer Comparison

    Brands

    Electral

    Corporate Actions

    Consolidated
    DATE
    DETAILS
    Show More
    Show Less
    Show More
    Show Less

    Suppliers

    • Sayaji Industries Ltd.

    FAQs on FDC Ltd. Business

    FDC Limited is a renowned pharmaceutical company in India, established in 1936. It focuses on producing top-notch products such as Oral Rehydration Salts (ORS) and prescription formulations with internationally accredited manufacturing units.

    FDC major competitors are Orchid Pharma, Guj. Themis Biosyn, Novartis India, Zota Health Care, Gufic Biosciences, Sanofi India, Bliss GVS Pharma.
    Market Cap of FDC is ₹5,463 Crs.
    While the median market cap of its peers are ₹4,976 Crs.

    FDC seems to be less financially stable compared to its competitors.
    Altman Z score of FDC is 4.04 and is ranked 7 out of its 8 competitors.

    Company Filing

    Discussions & Analysis

    Ideas Dashboard
    Results
    Timeline
    Watchlist
    Portfolio
    Alerts
    Stock Screener
    Market
    Raw Material